1Elevan Biopharmaceuticals, Inc.
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Patient access and affordability
Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
FDA-2025-N-6895-0001Notice
Comments
2,641
Last activity Jul 22, 2026
Deadline
Closed on Jul 23, 2026
Closed Jul 23, 2026
Net supportiSupport minus oppose · campaigns included
+86%
+86% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
- Posted
- Apr 16, 2026
- Comment period
- Apr 16, 2026 – Jul 23, 2026
- FR Doc
- 2026-07361
- Topics
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Analyzed 2,586 of 2,641 comments
98%· analysis in progress
Stance breakdown
+86%
Net support
Support2,336Oppose106Other144Not yet analyzed55
Aggregates include form-letter campaigns. Excluding them, net support is +86% across organic comments.
Who commented
Breakdown by commenter type.
Individual
2,463
Government
3
Trade association
8
Advocacy
14
Academic
6
Business
85
Other
7
Not yet analyzed
55
Comments over time
Weekly arrivals, stacked by stance.
Posted Apr 16, 2026Deadline Jul 23, 2026
Apr 13May 4May 25Jun 15Jul 6Jul 20
Support2,336Oppose106Other144
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
90%
4%
6%
Business
99%
1%
0%
Advocacy
71%
29%
0%
Trade association
38%
38%
25%
Other
71%
0%
29%
Academic
83%
17%
0%
Government
67%
33%
0%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Uncheck an issue to choose another.
| Organization | Compounding safety and access | Add specific peptides to 503a list | Peptide efficacy for healing | Patient access and affordability | Side effects of peptides |
|---|---|---|---|---|---|
1Elevan Biopharmaceuticals, Inc. BusinessSupport 1Elevan Biopharmaceuticals, Inc., a 503A compounding pharmacy, supports the inclusion of BPC-157, TB-500, MOTS-c, and Se | · | · | |||
Adaptogenics Inc. (operating as Human Extension Sciences) BusinessSupport Gurinder Sandhu, CEO of Adaptogenics Inc. | · | · | |||
Alpha & Omega Concierge PLLC BusinessSupport Richard Cron, an advanced practice registered nurse and founder of Alpha & Omega Concierge PLLC, argues in favor of incl | · | · | |||
American Academy of Peptide Medicine (AAPM) AdvocacySupport The American Academy of Peptide Medicine (AAPM) submits a formal request for the inclusion of seven specific peptide sub | · | · | |||
American Pharmacists Association (APhA) Trade associationOppose The American Pharmacists Association (APhA) opposes the inclusion of the nominated peptides on the 503A Bulks List at th | · | · | |||
BIOMOD Compounds LLC BusinessSupport BIOMOD Compounds LLC supports the inclusion of seven specific peptides on the Section 503A Bulk Drug Substances List, pr | · | · | · | ||
Coastline Wellness BusinessSupport Chris McKinley, Clinical Director of Coastline Wellness, supports including specific peptides (such as BPC-157 and TB-50 | · | · | |||
Collaborative for Evidence-Based Medicines (CEBM) AdvocacyOppose The Collaborative for Evidence-Based Medicines (CEBM) opposes the inclusion of the nominated peptide substances on the 5 | · | · | |||
Elysium Health, Inc. BusinessSupport Elysium Health, Inc. | · | · | |||
Foreviva Medical Clinic BusinessSupport Dr. | · | · | |||
IPEX Health BusinessSupport John Orton, CEO of IPEX Health, urges the Committee to include seven specific peptides on the 503A Bulk Drug Substances | · | · | |||
medical aesthetics and wellness clinic BusinessSupport Dr. | · | · | |||
Medisca, Inc. BusinessSupport Medisca, Inc., a global healthcare company and FDA-registered repackager, supports the inclusion of additional substance | · | · | · | · | |
Obesity Action Coalition AdvocacySupport The Obesity Action Coalition (OAC) supports the committee's efforts to ensure patient safety and product quality regardi | · | · | · | ||
Obesity Medicine Association AdvocacyOppose The Obesity Medicine Association (OMA) opposes the inclusion of MOTS-c on the section 503A Bulk Drug Substances List. | · | · | · | ||
Powers Family Pharmacy BusinessSupport Randy Powers, a compounding pharmacist at Powers Family Pharmacy, strongly supports including BPC-157 (free base and ace | · | · | |||
Texas Pharmacy Association Trade associationSupport The Texas Pharmacy Association supports adding seven nominated peptides to the Section 503A Bulk Drug Substances List fo | · | · |
Adaptogenics Inc. (operating as Human Extension Sciences)
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
Alpha & Omega Concierge PLLC
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
American Academy of Peptide Medicine (AAPM)
AdvocacySupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
American Pharmacists Association (APhA)
Trade associationOppose
Compounding safety and access
Add specific peptides to 503a list
Side effects of peptides
BIOMOD Compounds LLC
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Coastline Wellness
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
Collaborative for Evidence-Based Medicines (CEBM)
AdvocacyOppose
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
Elysium Health, Inc.
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Side effects of peptides
Foreviva Medical Clinic
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
IPEX Health
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Patient access and affordability
medical aesthetics and wellness clinic
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
Medisca, Inc.
BusinessSupport
Compounding safety and access
Obesity Action Coalition
AdvocacySupport
Compounding safety and access
Patient access and affordability
Obesity Medicine Association
AdvocacyOppose
Compounding safety and access
Add specific peptides to 503a list
Powers Family Pharmacy
BusinessSupport
Compounding safety and access
Add specific peptides to 503a list
Peptide efficacy for healing
Texas Pharmacy Association
Trade associationSupport
Compounding safety and access
Add specific peptides to 503a list
Patient access and affordability
2 organization-typed comments could not be identified.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Filter:
- Jul 22, 2026Comment from Davis LillySupportIndividual
A patient who successfully used peptide therapy to lose weight and improve their health supports the action. They urge the FDA to consider real-world patient experiences and preserve access to these therapies while maintaining safety standards.
Read comment → - Jul 22, 2026Comment from Kanevsky AlexSupportIndividual
An individual shares their personal positive experience using BPC-157 and TB-500 as part of a comprehensive recovery plan. They urge the FDA to consider real-world patient experiences and the totality of evidence when evaluating whether to include these peptides on the bulk drug substances list.
Read comment → - Jul 22, 2026Comment from Hammond MattSupportIndividualRead comment →
- Jul 22, 2026Comment from AnonymousSupportIndividual
A physician supports the inclusion of peptides in medicine, citing successful patient outcomes for orthopedic surgeries, chronic inflammation, and autoimmune diseases. The commenter advocates for the adoption of cellular medicine and peptide therapies as a proactive approach to treating chronic illness.
Read comment → - Jul 22, 2026Comment from Samuels CarolynSupportIndividualRead comment →
- Jul 22, 2026Comment from Franklin-Moytoy CaraOtherIndividual
The commenter shares a personal anecdote about their experience with GLP1/GIP peptides and the importance of sourcing them from reputable companies. They do not express a specific position on the proposed action regarding the Section 503A Bulk Drug Substances List.
Read comment → - Jul 22, 2026Comment from Bootz TammyOtherIndividual
The commenter shares a personal anecdote about how peptides have improved their health and quality of life while suffering from Rheumatoid Arthritis. They do not express a specific position on the proposed action regarding the Bulk Drug Substances List.
Read comment → - Jul 22, 2026Comment from Bazemore KimSupportIndividual
An individual shares a personal success story regarding the life-changing health benefits they experienced using GLP peptides. By highlighting their positive results and their use of accredited pharmacies, the commenter implicitly supports the inclusion of these substances on the bulk drug substances list.
Read comment → - Jul 22, 2026Comment from Baravik MarkSupportIndividual
The commenter advocates for the inclusion of peptide therapies in the discussion, arguing that they represent a valid and evolving area of medicine. They suggest that instead of dismissing these treatments, the committee should focus on establishing rigorous oversight, research, and quality standards.
Read comment → - Jul 22, 2026Comment from Pinciaro CarolOpposeIndividual
The commenter opposes the inclusion of bulk drug substances on the Section 503A list, arguing that it facilitates an unregulated market without physician oversight. They express concern that this action prioritizes revenue over patient safety, particularly regarding popular weight reduction drugs.
Read comment →